Robert W. Baird Cuts DENTSPLY SIRONA (NASDAQ:XRAY) Price Target to $31.00

DENTSPLY SIRONA (NASDAQ:XRAY) had its price objective decreased by Robert W. Baird from $33.00 to $31.00 in a research note released on Monday morning, Benzinga reports. Robert W. Baird currently has a neutral rating on the medical instruments supplier’s stock.

Several other equities research analysts have also recently commented on XRAY. Needham & Company LLC dropped their target price on shares of DENTSPLY SIRONA from $42.00 to $36.00 and set a buy rating for the company in a research report on Friday, May 3rd. Stifel Nicolaus lowered their price target on shares of DENTSPLY SIRONA from $30.00 to $28.00 and set a hold rating for the company in a research report on Thursday, July 18th. The Goldman Sachs Group lowered their price target on shares of DENTSPLY SIRONA from $34.00 to $30.00 and set a neutral rating for the company in a research report on Monday, May 6th. StockNews.com cut shares of DENTSPLY SIRONA from a buy rating to a hold rating in a research report on Friday, May 3rd. Finally, Piper Sandler reissued a neutral rating and set a $32.00 price target (down from $35.00) on shares of DENTSPLY SIRONA in a research report on Friday, May 3rd. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $33.67.

DENTSPLY SIRONA Trading Up 0.7 %

NASDAQ:XRAY opened at $26.24 on Monday. The company has a 50-day moving average price of $26.43 and a 200-day moving average price of $30.55. DENTSPLY SIRONA has a 12 month low of $23.94 and a 12 month high of $41.65. The company has a current ratio of 1.43, a quick ratio of 0.97 and a debt-to-equity ratio of 0.54. The stock has a market cap of $5.45 billion, a price-to-earnings ratio of -59.64, a P/E/G ratio of 1.18 and a beta of 1.01.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.42 EPS for the quarter, hitting the consensus estimate of $0.42. DENTSPLY SIRONA had a negative net margin of 2.41% and a positive return on equity of 11.54%. The firm had revenue of $953.00 million during the quarter, compared to analysts’ expectations of $969.45 million. During the same period last year, the company posted $0.39 EPS. The company’s quarterly revenue was down 2.6% compared to the same quarter last year. Equities analysts predict that DENTSPLY SIRONA will post 2.02 EPS for the current year.

DENTSPLY SIRONA Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, July 12th. Shareholders of record on Friday, June 28th were paid a dividend of $0.16 per share. The ex-dividend date was Friday, June 28th. This represents a $0.64 dividend on an annualized basis and a yield of 2.44%. DENTSPLY SIRONA’s dividend payout ratio is currently -145.45%.

Insider Buying and Selling at DENTSPLY SIRONA

In other news, Director Gregory T. Lucier acquired 3,577 shares of DENTSPLY SIRONA stock in a transaction on Friday, May 31st. The stock was acquired at an average cost of $27.95 per share, for a total transaction of $99,977.15. Following the purchase, the director now owns 58,374 shares in the company, valued at $1,631,553.30. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.52% of the stock is owned by company insiders.

Institutional Trading of DENTSPLY SIRONA

A number of large investors have recently made changes to their positions in XRAY. Raymond James Trust N.A. grew its stake in shares of DENTSPLY SIRONA by 32.2% in the fourth quarter. Raymond James Trust N.A. now owns 9,724 shares of the medical instruments supplier’s stock worth $346,000 after acquiring an additional 2,366 shares during the period. SG Americas Securities LLC grew its position in DENTSPLY SIRONA by 58.1% during the fourth quarter. SG Americas Securities LLC now owns 44,896 shares of the medical instruments supplier’s stock valued at $1,598,000 after buying an additional 16,507 shares during the period. Raymond James & Associates grew its position in DENTSPLY SIRONA by 29.8% during the fourth quarter. Raymond James & Associates now owns 1,021,226 shares of the medical instruments supplier’s stock valued at $36,345,000 after buying an additional 234,322 shares during the period. Raymond James Financial Services Advisors Inc. grew its position in DENTSPLY SIRONA by 123.8% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 13,706 shares of the medical instruments supplier’s stock valued at $488,000 after buying an additional 7,583 shares during the period. Finally, Bar Harbor Wealth Management bought a new stake in DENTSPLY SIRONA during the fourth quarter valued at approximately $4,931,000. 95.70% of the stock is currently owned by institutional investors.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.